Celgene Korea to negotiate Revlimid price
Published: 2012-09-05 06:56:00
Updated: 2012-09-05 06:56:00
The National Health Insurance Corporation (NHIC) will decide Celgene’s cancer drug Revlimid to be put on the positive list and how much it will cost through negotiations with Celgene Korea, according to pharmaceutical sources.
The Health Insurance Review and Assessment Service (HIRA said last...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
